GentiBio (Seed)
Funding Details
- Awarder
- Inbox
- Date Award
- August 05, 2020
- Vertical
- Biotherapeutics
- Funding URL
- View Funding Page
- Funding Amount:
- $20,000,000
Company Info
- Founders
- Adel Nada
- Company Description
- GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics.
- Market
- Autoimmune, alloimmune, autoinflammatory and allergic diseases
- Location
- Boston, MA, USA
- Coinvestors
- Novartis Venture Funds, OrbiMed Advisors, RA Capital Management